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The significant impact that this project is desired to have is to provide 
fundamental knowledge regarding the use of kudzu products for medicinal purposes, as it 
relates to antioxidant and anti-inflammatory effects. This is anticipated to be achieved by 
studying how the plant may alter the activity of several cytochrome P450 enzymes with 
known effects on human health. Different human cytochrome P450 isoforms were 
selected for this study based on their ability to convert relatively inert foreign chemical 
species into toxic metabolites. These include P450 2E1, 2A6, and 1A2. To analyze the 
selected enzymes in crude liver tissue each isoform had a unique substrate that was 
metabolized selectively.  
Several different kudzu extracts were prepared for analysis. Each extract and the 
pure compound puerarin were tested for inhibition of the enzymes. The most inhibitory 
effects were observed with the interaction between cytochrome P450 1A2 and the 
ethanolic kudzu root extract and cytochrome P450 2C9 and the ethanolic kudzu root 
extract.
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CHAPTER I 
 
BACKROUND 
 
 
Cytochrome P450 enzymes play a major role in the metabolism of xenobiotics 
such as carcinogens, drugs, steroids, and pesticides. They also metabolize fat-soluble 
vitamins, and endogenous compounds such as eicosanoids and mammalian alkaloids. 
Cytochrome P450s are a microsomal superfamily of isoenzymes,[1] and are the most 
important enzyme system in human phase I metabolism of foreign chemicals. [2] Their 
role in phase I metabolism is catalyzing the oxidation of foreign chemicals that enter the 
body.  [2] Regardless of what the compound is, it is important that the lipophilicity is 
reduced, so as not to accumulate in lipid membranes and that the compound is modified 
in such a way as to make it easier to remove. The general reaction through which 
cytochrome P450s accomplish such metabolism is shown in the reaction scheme NADPH 
+ H+ + O2 + R → NADP+ + H2O + ROH, where NADPH is the biological electron donor, 
R is the substrate, and ROH represents the oxidized product. The electrons are supplied 
from NADPH via the intermediary action of a flavoprotein, NADPH-CYP450 reductase. 
[2] In many cases this can produce less toxic or non-toxic metabolites; however, in 
several instances cytochrome P450 metabolism can be undesirable and result in toxic 
metabolites. Reactive oxygen species (ROS) can be generated from cytochrome P450 
metabolism that can cause oxidative stress. [3] In these instances, the inhibition of 
cytochrome P450 enzymes could actually limit the formation of ROS and cause an anti-
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oxidant effect. In some cases, during the course of oxidizing certain compounds, 
cytochrome P450s can undergo mechanism-based, “suicide”, inactivation, destroying 
itself in the process. [3] Alternatively, the inhibition or induction of cytochrome P450s 
can result in drug interactions and promote toxicity or reduce therapeutic effects, thus 
understanding interactions between P450s and natural dietary supplements is extremely 
important when considering the use of such products. [2] When looking at mammalian 
cytochrome P450s as a whole, it is also important to keep in mind that the catalytic 
sensitivity of these enzymes can vary between organisms, thus understanding the 
relationship between P450 isoforms across different species is an important consideration 
when selecting model systems to study. For example, the rat, rabbit, and human liver 
contain the P450 2E1 isoform, and the rodent models are often used to simulate the 
human enzyme, so recognizing differences in the interactions between natural products 
and the 2E1 found in rabbit, rat, and human cells is an important facet of drug 
metabolism studies. 
 The current study will focus on potential interactions between the natural product 
kudzu and specific cytochrome P450 isoforms found in rabbit and human liver cells. It 
will address systems, along with identification of optimal extraction methods to 
maximize inhibitory effects. The isoforms selected for the study include P450 2C9, 2E1, 
2A6, and 1A2 as described in the following sections. 
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Known Drug/Herb Interactions 
Cytochrome P450 2C9 
 Cytochrome P450 2C9 has been well characterized. There are crystal structures/x-
ray structures available for human cytochrome P450 2C9. The enzyme shows selectivity 
for small, lipophilic anions, such as ibuprofen. The hepatic total cytochrome P450 
content within a normal human liver is comprised of approximately 20% of the 
cytochrome P450 2C9 isoform, so it is not unexpected that approximately 15% of clinical 
drugs are metabolized by this enzyme. However, mutations within this enzyme do exist, 
and can greatly influence its functionality. [4] 
 Recent studies have shown that cytochrome P450 2C9 inhibition may be the cause 
of several drug-drug / drug-herb interactions with warfarin. [5] Multiple components in 
marijuana smoke, such as CBD and CBN, have been shown to be significant inhibitors of 
cytochrome P450 2C9, and warfarin has been shown to be metabolized significantly by 
cytochrome P450 2C9.  This seems to indicate that components in marijuana smoke may 
be contributing to side effects from warfarin, such as bleeding complications in patients 
who consume marijuana. Warfarin has been known to have a higher likelihood of 
complications than many medications, and this is just one example. A better 
understanding of cytochrome P450 2C9 inhibition may resolve many warfarin 
complications. [5] 
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Cytochrome P450 2E1 
There are many other situations where specific cytochrome P450 activity could 
have a negative effect. A well-known situation would be mixing specific medications 
with alcohol. Various medications are labeled with a warning such as “do not take with 
alcohol”. Alcohol can promote the activity of specific cytochrome P450 enzymes. This 
may produce toxic metabolites when mixed with specific medications, such as Tylenol, 
by causing chemicals, such as acetaminophen, to be processed by the cytochrome P450 
enzymes that display a promoted degree of activity when alcohol is consumed, such as 
cytochrome P450 2E1. When acetaminophen is metabolized by P450 2E1, it is oxidized 
to N-acetyl-p-benzoquinine-imine as illustrated in figure 4. This toxic intermediate can be 
excreted after it is conjugated to glucuronic acid and sulfate as displayed in the 
illustration below; however, the supply of glucuronic acid and sulfate may be depleted if 
this intermediate is produced in high concentrations. This intermediate will then start 
binding to cellular proteins and cause cell injury and death. [8] 
Through inhibiting cytochrome P450 2E1, the formation of the toxic 
acetaminophen metabolite N-acetyl-p-benzoquinine-imine can be drastically reduced as 
shown in the study conducted by Hazai et al. [9]. In this study cytochrome P450 2E1 
inhibitors 4-methyl pyrazol, Diethyl-dithiocarbamate, and disulfiram showed significant 
inhibition of the 2E1 isoform in a dose dependent manner. Disulfiram showed the most 
significant inhibition at about 20% at a 1 micromolar concentration and about 80% at a 
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50 micromolar concentration. This resulted in a reduction of the toxic metabolite 
produced from acetaminophen, NAPQI.  [9] 
 Cytochrome P450 2E1 is also known to catalyze the activation of certain 
nitrosamines, such as N-nitrosodiethylamine and N-nitrosodimethylamine, into genotoxic 
compounds. Inhibition of these enzymes was shown to reduce the production of these 
compounds by approximately 60 percent. [10] 
Cytochrome P450s can also be inhibited by certain foods, such as grapefruit. 
Grapefruit juice has displayed potent inhibition in assays for several cytochrome P450s 
including 3A4 and 2C9. Both Cytochrome P450 3A4 and 2C9 were inhibited by 
approximately 100% at 10% juice concentrations. This can be used to increase the 
bioavailability of certain medications, and in certain instances it can reduce the 
probability of ROS metabolites from cytochrome P450 metabolism. Kudzu extracts and 
products could potentially result in similar drug/natural product interactions. [11] 
 Cytochrome P450 2C9 is not the only isoform with the potential to experience 
drug/herb interactions. Cytochrome P450 2A6 metabolizes therapeutic agents such as 
halothane, valproic acid and losigamon, and cytochrome P450 2A6 can be significantly 
inhibited by chalepensin, a compound found in, Rutagraveolens L., Rue. Rue is 
commonly used in Asian cultures as an herbal remedy for a variety of ailments such as 
headache, wounds and rheumatics. Chalepensin was found to be a competitive inhibitor 
of CYP450 2A6, and the mechanism-based inhibitory properties displayed by the 
compound were significant enough to possibly result in chalepensin-induced toxicity 
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through CYP2A6 inactivation, reaching up to over 60% inhibition at a 3 μM 
concentration of chalepensin. [12] 
 Similarly, cytochrome P450 1A2 can also be affected by drug/herb interactions. 
Nuciferine, a compound extracted from Nelumbo nucifera Gaertn leaves, has displayed 
modest, but significant inhibition of CYP450 1A2 both in vivo and in vitro. The IC50 
value was determined to be 2.12 mmol/L in vitro; therefore, the inhibition of CYP450 
1A2 was significant enough that it would increase the risk of toxicity from other CYP450 
1A2 substrate drugs that may be co-administered. [13] 
Properties and uses of kudzu 
 Kudzu is currently used in many parts of the world for a variety of reasons from 
antioxidant capabilities to anti-inflammatory properties. [6] We propose that certain 
health effects of kudzu could be the result of their ability to inhibit several different 
human cytochrome P450 enzymes such as cytochrome P450 2A6 and 2E1. In this regard, 
kudzu could be more efficiently utilized as a therapeutic agent if it was better known 
which individual cytochrome P450 enzymes are reacting with each of the chemical 
components of kudzu that contribute to the inhibitory effects. 
The kudzu plant may be identified by looking for trifoliate, egg shaped, medium 
green leaves that are fuzzy to the touch. Kudzu leafs would be attached to long vines 
covered in small, bronze hairs. Trifoliate leaves are leaves that grow in sets of three from 
each node. The central leaf will have a leafstalk of about three quarters of an inch, and 
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the other leafs leafstalks will be much shorter. The seed pods look like hairy soy bean 
pods that are usually about two inches long. [7] 
 Kudzu has been well characterized with respect to its chemical composition as 
shown in figures 1, 2, and 3. [6] Puerarin is one of the most abundant compounds in 
kudzu root. Therefore, it is commonly used as a standard for quality control of medicinal 
materials produced from kudzu. This is part of the reason why puerarin was the first 
compound that was selected for testing in the current study. Puerarin has also been shown 
to possess antioxidant properties, hepatoprotective properties, anti-inflammatory 
properties, and etcetera. [6] A broad study was conducted to verify many of the beneficial 
effects attributed to puerarin. [6] The structure of puerarin is shown in table 1. The 
amount of different chemicals that are found in kudzu can vary to a substantial degree 
depending on where and when the plant is grown along with the preparation method used 
to produce the kudzu product; therefore, it is important to know the active constituents, so 
more accurate quality control standards can be established for a given application. [6] 
 The expected impact of this project is to increase the efficiency of the use of 
kudzu products for medicinal purposes, such as antioxidant and anti-inflammatory 
effects. This is anticipated to be achieved by contributing to the current knowledge about 
how the plant chemically aides in treatment of ailments by studying the impact kudzu 
products, and known chemical components of kudzu, have on several cytochrome P450 
enzymes. This project may also develop a more efficient procedure for the preparation of 
medicinal kudzu products. 
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Compound    A1  A2  A3  A4  A5 
             
Puerarin    H  H  Glc  H  H 
Daidzein    H  H  H  H  H 
Daidzin    H  Glc  H  H  H 
Genistein    OH  H  H  H  H 
Genistin    OH  H  H  H  H 
Formononetin    H  H  H  H  Me 
Biochanin A    OH  H  H  H  Me 
 
 
 
Figure 1. Structure of Known Flavonoids Found in Kudzu 
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Compound    A1  A2  A3 
         
Pueroside A    Glc 6‐Rha  H  H 
Pueroside B    Glc  Me  Glc 
(±)‐puerol B 2‐0‐
glucopyranoside    Glc  Me  H 
kuzubutenolide A  Glc  H  H 
 
 
Figure 2. Structures of Known Glycosides Found in Kudzu 
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Figure 3. The Structures of Several Additional Notable Constituents in Kudzu 
 
 
 
 
 
 
Compound    A1  A2  A3  A4 
           
Kudzusapogenol A    H  OH  OH  H 
Kudzusapogenol C    H  H  OH  H 
Kudzusapogenol A1    Glc A2‐ara2‐rha  o‐xyl  OH  OH 
Kudzusapogenol A2    Glc A2‐gal  OH  OH  OH 
Kudzusapogenol A3    Glc A2‐gal2‐rha  OH  OH  OH 
Soyasapogenol A    H  OH  OH  H 
Soyasapogenol B    H  OH  H  H 
CH3
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A
CH3CH3CH3
O
CH3
CH3
A
A
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A3      
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Ara: arabinose, Gal: galactose, 
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Figure 4. Acetaminophen Metabolic Pathways Involving Cytochrome P450s
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Preparation of Kudzu Extracts 
We have been utilizing a powdered kudzu root sample that was purchased from 
the Florida Herb House and grown in China. A simple procedure that was utilized to 
produce an ethanol extract from Morigaoleifera Lam. leafs for liver antioxidant studies 
was utilized for the current project as described below. [14] The procedure that was 
utilized began with obtaining about 10 grams of kudzu powder. The powder was inserted 
into a round bottom flask or jar with 100 mL of an 80 percent ethanol solution and a stir 
bar. The mixture was then allowed to stir for approximately 1 hour. The mixture was 
filtered with a Büchner funnel and filter flask, and the solution was then taken to the 
rotary evaporator to remove the ethanol. The rotary evaporator was set to 87 degrees and 
approximately 1 rotation every second. Once the ethanol was removed, the remaining 
extract was weighed and added to the desired amount of distilled water, normally 10 
milliliters, and warmed on a hot plate until the extract went into solution. The extract was 
stored in the freezer. 
Preparation of Kudzu Extract Fractions 
 A sample of the crude ethanolic kudzu root extract was partitioned utilizing a 
35cc Sep-pak C18 filter cartridge provided by the waters division of the millipore 
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corporation. The crude extract sample was introduced into the filter, and 5 mL aliquots of 
varying concentrations of ethanol were eluted through the filter and collected to obtain 
the extract fractions. An aqueous fraction, 10%, 20%, 40%, 70%, and 100% ethanol 
solution was utilized to make six different extract fractions. The extracts were than 
concentrated or diluted to obtain the desired concentration of each fraction. 
Cytochrome P450 Assays 
Cytochrome P450 2A6 Assay using fluorometric detection 
The cytochrome P450 2A6 fluorometric assay reactions consisted of 150 L of a 
100 mM phosphate buffer solution at a pH of 7.4, 50 μM of coumarin and 20 μg of 
microsomal protein. The mixture was vortexed for 10 seconds before adding 1mM 
NADPH. The mixture was then vortexed for 5 seconds and inserted into the incubator at 
37 degrees. After the solution was incubated for 20 minutes, the mixture was removed 
from the incubator and 25 μL of cold 2M hydrochloric acid was added to terminate the 
reaction. The mixture was then vortexed for 30 seconds to ensure that the reaction was 
thoroughly terminated. Then 450 μL of chloroform was added to the mixture. The 
mixture was then vortexed for approximately 30 seconds, and centrifuged at 3000 rpm for 
5 minutes. Then 300 microliters of the bottom layer was added to separate vials 
containing 1 mL of sodium borate buffer. The mixture was vortexed for 30 seconds, and 
then centrifuged for 5 minutes at 3000 rpm. Then 800 μL of the top layer was taken for 
testing in the fluorometer. Quantification of the 7-hydroxycoumarin product was 
accomplished using an excitation wavelength of 370 nm, and by monitoring emission 
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from 400-550 nm.  Due to inconsistencies related to the extraction required in this 
method, an alternative method was subsequently developed utilizing direct HPLC 
separation and detection of the product described in the next section. 
Cytochrome P450 2A6 Assay using HPLC detection 
The cytochrome P450 2A6 HPLC based assays are identical in procedure to the 
cytochrome P450 2E1 reactions except the substrate used was coumarin and the reactions 
were quenched with 10μL of 70% perchloric acid, placed on ice for 10 minutes, and then 
centrifuged for 5 minutes at 3000 rpm. Then the liquid samples were transferred to HPLC 
minivials for testing. The HPLC flow rate was 1.8 mL/minute. The LC run time was 9.05 
minutes, the detector wavelength was 320 nm, and the mobile phase used was 20% 
acetonitrile. 
Cytochrome P450 2E1 Assay 
The cytochrome P450 2E1 reactions consisted of 130 μL of distilled water, 100 
mM phosphate buffer at a pH of 7.4, 10 μg of microsomal protein, and 10 μM PNP. The 
mixture was then vortexed for 10 seconds, and 1 mM NADPH was added to reach a final 
volume of 200 μL. The mixture was then incubated at 37 degrees Celsius for 40 minutes. 
The vials were removed, and 400 μL of 3 percent, cold perchloric acid was added. The 
vials were placed in ice for 10 minutes, and then the vials were centrifuged for 5 minutes 
at 3000 rpm. A 500 μL aliquot of the sample was transferred to HPLC vials to be 
analyzed. The column used for all HPLC assays was a C18 column with a 5 μ pore size 
and measured 15 cm by 4.6 mm. The flow rate for the 2E1 assay was 1.5 mL/minute, 
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with run times of 12.5 minutes and the detection wavelength was 340 nm, and the mobile 
phase was 20% acetonitrile. 
Cytochrome P450 1A2 Assay 
The cytochrome P450 1A2 HPLC based assay reactions consisted of 0.10 M 
phosphate buffer solution at a pH of 7.4, 97.5μM 7-ethoxycoumarin solution, and 20 μg 
of microsomal protein. The mixture was vortexed for 5 seconds before adding 1mM 
NADPH. The mixture was then incubated at 37 degrees Celsius. After the solution was 
incubated for 30 minutes, the mixture was removed from the incubator and 10μL of 70% 
Perchloric acid was added to terminate the reaction. The mixture was then vortexed for 5 
seconds, set in ice for 10 minutes, and then centrifuged for 5 minutes at 3000 rpm. Then 
the liquid samples were transferred to HPLC minivials for testing. In this assay, the 
product was identical to that formed in the 2A6 assay, so HPLC conditions used were the 
same as those described in the previous section except the LC and detector run times 
were 16 minutes to allow enough time for the substrate to elute from the column. 
Cytochrome P450 2C9 Assay 
 The cytochrome P450 2C9 HPLC based assay reactions consisted of 0.10 M 
phosphate buffer solution at a pH of 7.4, 60μM dichlofenac, and 20 μg of microsomal 
protein. The mixture was vortexed for 5 seconds before adding 1mM NADPH. The 
mixture was then inserted into the incubator at 37 degrees Celsius. After the solution was 
incubated for 40 minutes, the mixture was removed from the incubator and 100μL of a 
94% acetonitrile, 6% glacial acetic acid solution was added to terminate the reaction. The 
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mixture was then vortexed for 5 seconds, set in ice for 10 minutes, and then centrifuged 
for 5 minutes at 4000 rpm. An aliquot of the liquid samples were transferred to HPLC 
minivials for analysis. The mobile phase utilized for this procedure was 50% acetonitrile 
with a 20 mM phosphoric acid concentration. The LC and detector run times were 15 
minutes with a flow rate of 1 mL per minute and a detection wavelength of 220 nm. 
Inhibition studies 
To probe for inhibition, the assays described above were carried out in the 
presence of various kudzu extracts along with the compound puerarin to assess the ability 
of each to interfere with cytochrome P450 metabolism. Concentrations used in the 
individual experiments are described in the results section.
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
 
Effects of Kudzu Extracts and Puerarin on Rabbit Liver Cytochrome P450s 
 
Inhibition of rabbit liver P450 2E1 
The rabbit enzyme model was chosen initially as a model for the human 
cytochrome P450 activity based on its availability and accepted similarity to the human 
enzyme. 
Inhibition of Rabbit Liver P450 2E1 by an Ethanolic Kudzu Root Extract 
The 2E1 isoform of P450 is important toxicologically because of its ability to 
activate toxins, thus it was the first isoform chosen for evaluation of the inhibitory effects 
of kudzu extracts and puerarin 
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Figure 5. Dose Dependent Effects of an Ethanolic Kudzu Root Extract on the 
Metabolism of p-nitrophenol by Cytochrome P450 Enzymes Found in Rabbit Liver 
 
 
The ethanol extract from kudzu root powder was examined first, and as shown in 
figure 5, this extract produced modest inhibition of cytochrome P450 2E1 activity at 
concentrations ranging from 20-201g/mL. Approximately 13%, of the activity was lost 
when a 20 g/mL concentration was included in the reaction, and this inhibition 
increased to approximately 45% at the highest dose utilized, 201g/mL.   
 
 
 
 
19 
 
Inhibition of Rabbit Liver P450 2E1 by a Kudzu Root Extract Prepared Utilizing 
Chloroform 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The Results from a Rabbit Cytochrome P450 2E1 Dose Dependent 
Assay Conducted in the Presence of a Kudzu Root Extract Prepared Utilizing 
Chloroform Rather than Ethanol 
 
 
No inhibition was observed in the chloroform extract, as shown in figure 6. 
Chloroform is a very non-polar solvent that is used to extract non-polar constituents of 
the plant, and since P450 active sites tend to be non-polar, generally good inhibitors are 
isolated from this fraction. The data shows that there are no non-polar constituents in the 
kudzu extract with strong P450 inhibitory properties. Although the inhibition was not 
dramatic, it is significant that at the lowest dose utilized, there was measureable 
inhibition. The dose response curve was not typical of a competitive reversible inhibitor, 
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as one would expect a larger effect upon increasing the concentration by 10-fold (200 
g/mL). 
Inhibition of Rabbit Liver P450 2E1 by Puerarin 
 
 
  
Figure 7. The Effects of Puerarin on Cytochrome P450 2E1 Metabolism was 
Studied through a Dose Dependent Assay Utilizing Rabbit Liver Microsomes 
 
 
Minor inhibition was exhibited, though only 25%, in the presence of puerarin at a 
1mM concentration. This concentration is extremely high, and unlikely to be of any 
physiological significance indicating a P4502E1-puererin interaction in vivo is highly 
unlikely. The results shown in figure 7 involved the rabbit isoform; however, a 
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comparison with the human P4502E1 is necessary before a conclusive statement 
regarding drug interactions in the human body could be made. 
Inhibition of rabbit liver P450 2A6 
Inhibition of Rabbit Liver P450 2A6 by an Ethanolic Kudzu Root Extract 
The 2A6 isoform of P450’s has similar importance toxicologically as the 2E1 
isoform because of its analogous ability to activate toxins, thus it was the second isoform 
chosen for evaluation of the inhibitory effects of kudzu extracts and puerarin. 
 
 
 Figure 8. The Results from a Dose Dependent Rabbit  
Cytochrome P450 2A6 Assay Performed in the Presences of an Ethanolic Kudzu 
Root Extract 
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 No inhibition was displayed in the presence of the ethanolic kudzu root extract up 
to 35 mg/mL; however, at the highest concentration used 150 mg/mL a substantial 
reduction in activity was observed, suggesting that certain components of the kudzu are 
capable of inhibiting this isoform. The average background activity was removed from 
these results, so the apparent negative activity at the highest concentration represents 
close to complete inhibition. Based on the results shown in figure 8, the rabbit P450 2A6 
is not significantly inhibited by the ethanolic kudzu root extract, as even 35 mg/mL is 
extremely high for physiological significance. 
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Inhibition of Rabbit Liver P450 2A6 by Puerarin 
 
 
  
Figure 9. Results Obtained from a Dose Dependent Assay Testing the Effects 
of Puerarin on Rabbit Cytochrome P450 2A6 
 
Experiments were carried out in duplicate, and the results of each individual trial 
are shown in figure 9.  The results displayed minor inhibition. Approximately 30% 
inhibition in the presence of puerarin at a 0.231 mM concentration with the peak area 
decreasing from about 68K to 48K was observed and ~66% inhibition in the presence of 
puerarin at a 1mM concentration with the peak area decreasing from 68K to 25K 
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Inhibition of rabbit liver P450 1A2 
Inhibition of Rabbit Liver P450 1A2 by an Ethanolic Kudzu Root Extract 
The 1A2 isoform of P450’s has similar importance toxicologically as the 2E1 and 2A6 
isoform because of its analogous ability to activate toxins, thus it was the second isoform 
chosen for evaluation of the inhibitory effects of kudzu extracts and puerarin. 
 
 
  
Figure 10. Effects of Varying Concentrations of an Ethanolic Kudzu Root 
Extract on 7-ethoxycoumarin Metabolism by Cytochrome P450 1A2 Enzymes 
Found in Rabbit Liver 
 
 
As displayed in figure 10, modest inhibition of cytochrome P450 1A2 was 
displayed in the presence of an ethanolic kudzu root extract. Roughly 25% inhibition was 
displayed at the lowest concentration, 20 g/mL, with the peak area reducing from about 
25,000 to 18,000 and increased to near 50% inhibition at the highest concentration, 201 
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g/mL with the peak area reducing from about 25,000 to 13,000. Similar to the results in 
figure 5, the dose response curve is not typical of a competitive reversible inhibitor. 
Based on the observed results, it is apparent that the 1A2 isoform is more susceptible to 
inhibition by the ethanolic kudzu extract than the 2E1 isoform. 
Inhibition of Rabbit Liver P450 1A2 by a Kudzu Root Extract Prepared Utilizing 
Chloroform 
 
 
 Figure 11. Effects of Varying Concentrations of a Kudzu Extract Prepared 
Utilizing Chloroform on 7-ethoxycoumarin Metabolism by Cytochrome P450 1A2 
Enzymes Found in Rabbit Liver 
 
 
 Figure 11 shows minor inhibition of approximately 29%, at 201 g/mL; whereas, 
the ethanolic kudzu root extract achieved this at approximately a 10 fold less 
concentration. The ethanolic kudzu root extract also started to show notable inhibition at 
a much lower concentration. The chloroform kudzu root extract only showed 4% 
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inhibition at 20 g/mL, and the ethanolic kudzu root extract showed about 25% inhibition 
at the same concentration. 
Inhibition of Rabbit Liver P450 1A2 by Puerarin 
 
 
Figure 12. The Effects of Varying Concentrations of Puerarin on 7-
ethoxycoumarin Metabolism by Cytochrome P450 1A2 Enzymes Found in Rabbit 
Liver 
 
 
 As shown in figure 12, the rabbit liver cytochrome P450 1A2 isoform displayed 
3% inhibition in the presence of a 50 concentration of puerarin. Considering this is a 
pure compound, puerarin seems as though it would have a minor impact on the total 
inhibitory potential against rabbit liver cytochrome P450 1A2 metabolism displayed by 
any extract. 
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Inhibition of rabbit liver P450 2C9 
The 2C9 isoform of P450’s has a different importance toxicologically compared to the 
other isoforms tested previously. This isoform metabolizes many pharmacological and 
commonly consumed compounds. Some of these compounds have been known to be 
commonly involved in drug-drug and drug-herb interactions such as warfarin. For this 
reason, it was a good candidate for evaluation of the inhibitory effects of kudzu extracts 
and puerarin. 
Inhibition of Rabbit Liver P450 2C9 by an Ethanolic Kudzu Root Extract 
 
 
 Figure 13. The Effects of an Ethanolic Kudzu Root Extract on Dichlofenac 
Metabolism by Cytochrome P450 2C9 Utilizing Rabbit Liver Microsomes  
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A significant amount of inhibition was displayed as illustrated in figure 13, 74% 
inhibition, in the presence of the ethanolic kudzu root extract at a concentration of 20 
g/mL. The interaction has an IC50 value of approximately 15 g/mL. 
Inhibition of Rabbit Liver P450 2C9 by a Kudzu Root Extract Prepared Utilizing 
Chloroform 
 
 
Figure 14. The Effects of Varying Concentrations of a Kudzu Extract 
Prepared Utilizing Chloroform on Dichlofenac Metabolism by Cytochrome P450 
2C9 Enzymes Found in Rabbit Liver  
 
 
Figure 14 displays minor inhibition. Roughly 12% inhibition was displayed at a 
49 g/mL concentration of the extract. This is approximately 6 fold less of an effect 
compared to the ethanolic kudzu root extract at a 20 g/mL concentration. Once again the 
29 
 
ethanolic kudzu root extract displayed much more inhibitory potential than the kudzu 
chloroform extract.  
Inhibition of Rabbit Liver P450 2C9 by Puerarin 
 
 
 Figure 15. The Effects of Puerarin on Dichlofenac Metabolism by 
Cytochrome P450 2C9 in Rabbit Liver Microsomes  
 
 
Figure 15 illustrates minor inhibition. Approximately 18% inhibition was 
displayed, in the presence of puerarin at a concentration of 25 M. Similar to the rabbit 
cytochrome P450 1A2 isoform, puerarin seems to be displaying a minimal contribution to 
the inhibitory potential displayed by any extract obtained from the kudzu root. 
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Effects of Kudzu Extracts and Puerarin on Human Liver Cytochrome P450 in Live 
S9 Fraction 
After utilizing the rabbit liver model, the results were utilized to conduct a more 
targeted, activity guided study with the human liver model due to the more limited supply 
of enzymes. The human liver model was utilized to more accurately represent in-vivo 
testing with human subjects. 
Inhibition of human liver P450 2E1 
Inhibition of Human Liver P450 2E1 by an Ethanolic Kudzu Root Extract 
 
 
  Figure 16. The Effects of an Ethanolic Kudzu Root Extract on PNP 
Metabolism by Cytochrome P450 2E1 
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To more accurately investigate possible interactions the ethanolic kudzu root 
extract would exhibit in vivo with cytochrome P450 2E1, human liver microsome testing 
was carried out. As illustrated in figure 16, approximately 20% inhibition was displayed 
in the presence of 49 g/mL of the crude ethanolic kudzu root extract. This is comparable 
to the results of 23% obtained utilizing rabbit liver enzymes. 
Inhibition of Human Liver P450 2E1 by Puerarin and a Kudzu Root Extract Prepared 
Utilizing Chloroform 
 
 
Figure 17. The Effects of Varying Concentrations of Puerarin and a Kudzu 
Extract Prepared Utilizing Chloroform on Dichlofenac Metabolism by Cytochrome 
P450 2C9 Enzymes Found in Human Liver 
 
 
To more accurately investigate possible interactions the kudzu root extract that 
was prepared utilizing chloroform would exhibit in vivo with cytochrome P450 2E1, 
human liver microsome testing was carried out. The results are shown in figure 17. 
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Approximately 12% inhibition was displayed in the presence of 49 g/mL of the crude 
chloroform kudzu root extract, and approximately 18% inhibition was displayed in the 
presence of puerarin at a 25M concentration. This is comparable to the results of 7% 
inhibition obtained utilizing rabbit liver enzymes with a 49 g/mL concentration of the 
crude chloroform kudzu root extract. Puerarin was not used in the same concentration in 
the rabbit liver testing; however, there was also no significant inhibition displayed. 
Inhibition of human liver P450 2A6 
Inhibition of Human Liver P450 2A6 by an Ethanolic Kudzu Root Extract 
 
 
Figure 18. Effects of an Ethanolic Kudzu Root Extract on Coumarin 
Metabolism by Cytochrome P450 2A6 Utilizing Human Liver Microsomes  
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A minor amount of inhibition was displayed, 15% inhibition, in the presence of 
the ethanolic kudzu root extract at a concentration of 49 g/mL, as shown in figure 18. 
These results suggest that the human cytochrome P450 2A6 isoform is more susceptible 
to inhibition by compounds in this extract than the rabbit cytochrome P450 2A6 isoform. 
The rabbit liver cytochrome P450 isoform did not display inhibition with up to a 35 
mg/mL concentration of the ethanolic kudzu root extract. 
Inhibition of Human Liver P450 2A6 by Puerarin and a Kudzu Root Extract Prepared 
Utilizing Chloroform 
 
 
Figure 19. Effects of a Kudzu Root Extract Prepared Utilizing Chloroform 
on Coumarin Metabolism by Human Cytochrome P450 2A6  
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The results illustrated in figure 19 display a minor amount of inhibition, 15% 
inhibition, in the presence of puerarin at a 101 M concentration. Minor inhibition was 
also displayed by the kudzu root extract prepared utilizing chloroform, 16% inhibition at 
a 201 g/mL concentration.  
Inhibition of human P450 1A2 
Inhibition of Human P450 1A2 Supersomes by an Ethanolic Kudzu Root Extract  
 
 
 Figure 20. Effects of an Ethanolic Kudzu Root Extract on 7-ethoxycoumarin 
Metabolism by Cytochrome P450 1A2 Utilizing Human Supersomes 
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The results from figure 10 prompted a comparison between results obtained from 
rabbit liver microsomes and supersomes; therefore, a dose dependent assay was 
conducted utilizing cytochrome P450 1A2 supersomes in the presence of the crude 
ethanolic kudzu root extract. Significant inhibition, approximately 61%, was displayed in 
the presence of the crude ethanolic kudzu root extract at 49 g/mL.  The IC50 value is 
approximately 17 g/mL.  
Inhibition of Human Liver P450 1A2 by a Kudzu Root Extract Prepared Utilizing 
Chloroform 
 
 
 Figure 21. Effects of a Kudzu Root Extract Prepared Utilizing Chloroform 
on 7-ethoxycoumarin Metabolism by Human Cytochrome P450 1A2 Enzymes 
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To more accurately predict any in vivo interactions, human liver microsomes 
were used to observe any interaction between a kudzu root extract prepared utilizing 
chloroform and human cytochrome P450 1A2. The results are illustrated in figure 21. 
Similar to the rabbit model, no significant inhibition was displayed. The human and 
rabbit liver models displayed 7% and 6% inhibition respectively in the presence of a 49 
g/mL concentration of the chloroform kudzu root extract; however, there was a notable 
difference between the rabbit and human liver microsomes at a 201 g/mL concentration. 
The rabbit and human liver cytochrome P450 1A2 microsomes showed 30% and 19% 
inhibition, respectively, at a 201 g/mL concentration of the chloroform kudzu root 
extract. 
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Inhibition of Human Liver P450 1A2 by Puerarin 
 
 
  Figure 22. Effects of Puerarin on Human Cytochrome P450 1A2 Metabolism 
of 7-ethoxycoumarin 
 
 
To more accurately investigate possible interactions puerarin would exhibit in 
vivo with cytochrome P450 1A2, human liver microsome testing was carried out. As 
illustrated in figure 22, approximately 15% inhibition of human cytochrome P450 1A2 
was displayed in the presence of puerarin at a 50 concentration. Puerarin has not 
shown significant inhibition across all studies. These results suggest that the human 
cytochrome P450 1A2 isoform is more susceptible to inhibition by the components 
within the ethanolic kudzu root extract and puerarin than the rabbit cytochrome P450 
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1A2 isoform. The human and rabbit liver microsomes showed about 15 and 3 percent 
inhibition, respectively, in the presence of puerarin at a 50 concentration. 
Inhibition of human P450 2C9 
Inhibition of Human Liver P450 2C9 by an Ethanolic Kudzu Root Extract 
 
 
 Figure 23. Effects of an Ethanolic Kudzu Extract on Human Cytochrome 
P450 2C9 Metabolism of Dichlofenac 
 
 
An assay with limited extract concentrations was performed to determine 
promising human cytochrome P450 interactions with the ethanolic kudzu root extract. As 
displayed in figure 23, modest inhibition was exhibited by human cytochrome P450 2C9 
enzymes in the presence of an ethanolic kudzu root extract. Modest inhibition was 
observed at 49 g/mL approximately 49% inhibition was displayed.  
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Inhibition of Human Liver P450 2C9 by an Ethanolic Kudzu Root Extract 
 
 
 Figure 24. Effects of an Ethanolic Kudzu Extract on Human Cytochrome 
P450 2C9 Metabolism of Dichlofenac 
 
 
After obtaining the results from figure 23, a dose dependent assay was preformed 
to further investigate the potential inhibitory effects the ethanolic kudzu root extract may 
display against cytochrome P450 2C9 metabolism. The results are shown in figure 24. 
Modest inhibition was observed, approximately 35% inhibition was displayed at 49 
g/mL, and about 41% inhibition was displayed at 201 g/mL. The difference in results 
at the 49 g/mL concentration may be due to the fact that the batch of human liver 
40 
 
microsomes was depleted with the test documented in figure 23 and a new batch was 
started. 
Inhibition of Human Liver P450 2C9 by Various Possible Inhibitors 
 
 
 Figure 25. The Most Substantial Effects Observed From Any Ethanolic 
Kudzu Extract Fraction on Cytochrome P450 2C9 Metabolism of Dichlofenac 
 
 
The 2C9 isoform displayed modest inhibition under certain circumstances, so a 
more complete screening of the isoform was preformed. The results from the most 
significant interaction are displayed in figure 25. Puerarin displayed no inhibition against 
the 2C9 supersome metabolism, and the chloroform extract showed little signs of 
inhibition. Significant inhibition, approximately 56%, was displayed at a 50 g/mL 
concentration of the 70% ethanol fraction prepared from the crude ethanolic kudzu root 
extract. Minor inhibition was observed by the kudzu root extract prepared utilizing 
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chloroform, 16% at 201 g/mL. No significant inhibition was displayed in the presence 
of puerarin. The kudzu extract prepared utilizing chloroform showed several notable 
interactions during cytochrome P450 testing. The kudzu root extract prepared utilizing 
chloroform displayed approximately 29% inhibition against rabbit liver cytochrome P450 
1A2 metabolism of dichlofenac at a 201g/mL concentration and 12% inhibition of 
rabbit liver cytochrome P450 2C9 at a 29 g/mL concentration. 
Effects of Active Ethanol Fractions on Individually Expressed 1A2 and 2C9 
Supersomes 
The supersome model was utilized to further investigate the most significant 
interactions found in the human and rabbit liver models due to its high activity and the 
selective nature of the enzymes. Supersome samples only contained the human isoform 
of interest. 
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Inhibition of human liver P450 1A2 supersomes 
Inhibition of Human Liver P450 1A2 Supersomes by an Ethanolic Kudzu Root Extract 
 
 
  Figure 26. Effects of Several Ethanolic Kudzu Extract Fractions on 
Cytochrome P450 1A2 Metabolism of 7-ethoxycoumarin 
 
 
Cytochrome P450 1A2 showed the second most potential for inhibition in the 
presence of the crude ethanolic kudzu root extract; therefore, a broad screening was 
conducted utilizing the ethanolic kudzu root extract fractions and isolated human liver 
supersomes. As shown in figure 26, the 20% ethanol fraction prepared from the crude 
ethanolic kudzu root extract showed the most potential for inhibition. Approximately 
40% inhibition was displayed in the presence of 50 g/mL of the 20% ethanol fraction. 
Modest inhibition was also displayed in the presence of the 70% ethanol fraction 
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prepared from the crude ethanolic kudzu root extract. No significant inhibition was 
displayed by any other extract fraction. 
Inhibition of P450 1A2 Supersomes by the 20% Ethanol Fraction of an Ethanolic 
Kudzu Root Extract 
 
 
Figure 27. Effects of the Ethanolic Kudzu Extract Fraction with the Most 
Substantial Interaction on Human 1A2 Supersome Metabolism of 7-
ethoxycoumarin 
 
 
The results presented in figure 27 prompted a dose dependent assay to investigate 
the affects that the 20% ethanol fraction prepared from the crude ethanolic kudzu root 
extract would have on cytochrome P450 1A2 metabolism. Supersome samples were 
utilized for this assay. Modest inhibition of the cytochrome P450 1A2 supersomes was 
exhibited in the presence of this fraction obtained from the crude ethanolic kudzu root 
extract; approximately 43% inhibition was displayed at 50 g/mL. Approximately 65% 
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inhibition was observed at the highest concentration, 200 g/mL. The IC50 value is 
approximately 40-90 g/mL. The crude ethanolic extract inhibits 50% at 20 g/mL, 
while the most active fraction (20%) only shows 43% inhibition at 50 g/mL. 
Inhibition of P450 2C9 supersomes 
Inhibition of P450 2C9 Supersomes by Ethanolic Kudzu Root Extract Fractions 
 
 
 
 Figure 28. Effects of Several Ethanolic Kudzu Extract Fractions on 
Cytochrome P450 2C9 Metabolism of Dichlofenac 
 
 
To further investigate the results from figure 28, an activity guided partial 
fractionation was conducted utilizing the ethanolic kudzu root extract. The extract 
fractions from the crude ethanolic kudzu root extract were obtained to enrich and further 
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isolate compounds responsible for the inhibition observed by the crude ethanolic kudzu 
root extract. A screening of all extract fractions was preformed. Minor inhibition was 
displayed in the presence of the aqueous fraction and the 10% ethanol fraction prepared 
from the crude ethanolic kudzu root extract, approximately 14% inhibition at an 11 
g/mL concentration. 
Inhibition of P450 2C9 Supersomes by Ethanolic Kudzu Root Extract Fractions 
 
 
 
 Figure 29. Effects of Several Ethanolic Kudzu Extract Fractions on 
Cytochrome P450 2C9 Metabolism of Dichlofenac 
 
 
To further investigate the results from figure 24, an activity guided partial 
fractionation was conducted utilizing the ethanolic kudzu root extract. As shown in figure 
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29, the extract fractions from the crude ethanolic kudzu root extract were obtained to 
enrich and further isolate compounds responsible for the inhibition observed by the crude 
ethanolic kudzu root extract.  
A screening of all extract fractions was preformed. Out of all of the extract 
fractions prepared from the crude ethanolic kudzu root extract, the 70% ethanol fraction 
displayed the most inhibition, 32% inhibition at 50 g/mL. 
Inhibition of P450 2E1 supersomes 
Validation of Puerarin Data Using Supersomes 
 
 
 
Figure 30. Effects of Puerarin on Human Cytochrome P450 2E1 Supersome 
Metabolism of PNP 
 
 
For comparison, a screening of the 2E1 isoform was conducted with supersomes 
as well. As shown in figure 30, approximately 37% inhibition was displayed in the 
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presence of puerarin at a 49 g/mL concentration. This indicates that the supersomes for 
the 2E1 isoform are also more susceptible to inhibition by this compound than the 2E1 
human liver microsomes. No inhibition was displayed when investigating this interaction 
with human liver microsomes. Puerarin showed little notable inhibition throughout all 
studies. The most notable interactions involving puerarin were the human liver 
cytochrome P450 1A2 interaction which displayed about 15% inhibition at a 50 M 
concentration, the rabbit liver cytochrome P450 2E1 isoform which displayed about 25% 
inhibition at a 1mM concentration, and the rabbit liver cytochrome P450 2A6 interaction 
which displayed 30% inhibition at a 0.231 mM concentration. 
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Table 1. Rabbit Liver Microsome Results 
 
 
 
 
 
 
 
 
Rabbi
t Puerarin Chloroform extract 
Ethanol 
Extract 
1A2 
Puerarin did not show 
signs of inhibition. 
~29% Inhibition at 201 
micrograms/mL 
~25% 
inhibition at 
20 
micrograms/
mL 
2C9 
The dose dependent 
assay showed no 
signs of inhibition. 
~12% inhibition at 49 
micrograms/mL 
Complete 
inhibition 
was 
observed at 
49 
micrograms/
mL 
2 E1 
~25% Inhibition at 1 
mM No Inhibition 
~25% 
inhibition at 
20 
micrograms/
mL 
2A6 30% at .231 mM 
The preliminary screening 
indicated that this potential 
interaction was not worth 
further investigation. 
No 
Inhibition 
up to 35 
mg/mL 
49 
 
Table 2. Human Liver/Supersome Results 
 
Human/Supe
rsomes Puerarin 
Chloroform 
extract Ethanol Extract 
1A2 
~15% 
inhibition at 
50 
micromolar 
concentration
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not worth 
further 
investigation. 
~ 61% inhibition at 49 g/mL, 
IC50 ~17 g/mL 
(supersomes) 
2C9 
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not 
worth further 
investigation.
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not worth 
further 
investigation. 
~35% inhibition at 49 
micrograms/mL 
2 E1 
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not 
worth further 
investigation.
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not worth 
further 
investigation. 
~12% inhibition at 201 
micrograms/mL(supersomes) 
2A6 
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not 
worth further 
investigation.
The 
preliminary 
screening 
indicated that 
this potential 
interaction 
was not worth 
further 
investigation. 
The dose dependent assay 
showed no signs of inhibition. 
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Table 3. Human Liver/Supersome Results Continued 
 
 
 
   
Human/Su
persomes 
Ethanol 
Extract 
Fractions 
Ethanol Extract 
Fractions of 
Interest 
Ethanol Extract 
Additional 
Fractions of 
Interest 
Initial Screening 
of Extracts 
1A2 
20% 
fraction 
~40% 
inhibition at 
50 
micrograms/
mL 
20% fraction 
~43% inhibition 
at 50 
micrograms/mL 
IC50 ~ 40 
micrograms/mL 
(supersomes) ND ND________ 
2C9 
The other 
Ethanol 
Extract 
fractions 
showed 
little to no 
inhibition. 
~32% inhibition 
at 50 
micrograms/mL 
~14% 
inhibition at 11 
micrograms/mL 
~49% inhibition 
at 49 
micrograms/mL 
2 E1 ND ND ND 
~20% inhibition 
at 49 
micrograms/mL 
2A6 ND ND ND ND 
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Activity Guided Study Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Summary of Activity Data for All Models, Extracts, and Pure 
Compounds Tested 
 
 
 
 
 
 
 
 
 
  
Chloroform Ethanol
Rabbit Human Rabbit Human
1A2   2C9   2A6   2E1 1A2   2C9   2A6   2E1 1A2   2C9   2A6   2E1
1A2  2C9   2A6   2E1
Extract Fractions
Human
1A2   2C9   2A6   2E1
Chemical Constituents
Puerarin
HumanRabbit
1A2   2C9   2A6   2E1
1A2   2C9  2A6  2E1
SupersomesSupersomes
1A2 2C9 2A6 2E1 1A2  2C9  2A6  2E1 
Supersomes
1A2  2C9  2A6  2E1
Supersomes
1A2   2C9   2A6   2E1
The isoforms in red displayed 
modest or significant 
interactions and the isoforms in 
green displayed little to no 
interaction. 
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 The data gathered from the assays represented in figure 33 shows that the 
ethanolic kudzu root extract is a slightly more potent inhibitor of Cytochrome P450 2E1 
enzymes than Puerarin alone. Cytochrome P450 1A2 and 2E1 displayed modest dose 
dependent inhibition in the presence of the ethanolic Kudzu root extract. Throughout the 
study multiple inhibitory interactions were observed; however, the two most substantial 
interactions were the reactions the 1A2 and 2C9 isoforms had in the presence of the 
ethanolic kudzu root extract. A comparison of the inhibition observed by all four 
isoforms in the presence of the different microsomes indicates that the supersomes have 
the most susceptibility to the inhibitory properties displayed by these extracts, and the 
rabbit liver microsomes displayed the least susceptibility to any inhibitory properties 
displayed by these extracts.  
The chloroform extract showed little inhibitory potential across the entire study. 
This is unexpected because P450 sites are generally non-polar, and the chloroform extract 
would have contained the more non-polar compounds from the kudzu root samples. 
Puerarin also displayed little inhibitory potential throughout the study. Puerarin was 
expected to display more inhibition because it is used as a standard for quality control in 
many kudzu products. The 1A2 supersomes also displayed substantially more 
susceptibility to the ethanolic kudzu root extract than the human liver microsomes and 
the rabbit liver microsomes. From the results obtained, kudzu appears to be safe for 
human consumption.
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